diabetic retinopathy

May 07, 2024

Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia  Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular is...

Aug 22, 2023

Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals’ EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retin...

Jun 03, 2022

Diabetic Retinopathy (DR), a microvascular disease, is an eye condition in diabetic patients, affecting blood vessels in the retina and causing significant visual loss in working populations. The retina needs a constant supply of blood, which it receives through a network of tiny blood vessels. Constant high blood ...

Jun 16, 2021

The eyes are one of the most precious and delicate parts of the human body. Around 80% of the information from the surrounding environment that the human perceives comes from our eyes. The eyes require the best protection and care, as a slight disability can severely impact day-to-day activities and can also have l...

Sep 13, 2018

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through V...